BPI-2021 is high effective and selective self-developed c-MET inhibitor. Abnormal expression of MET has been observed in a variety of cancers, including gastric, hepatocellular, and non-small cell lung cancer. Since MET signaling pathway plays an important role in the occurrence and development of non-small cell lung cancer and the resistance of EGFR-TKI, MET has become an important molecular therapeutic target for NSCLC after EGFR and ALK. Multiple studies have shown that EGFR-TKI combined with c-Met inhibitors can effectively overcome EGFR-TKI resistance.

BPI-2021 in xenograft animal model demonstrated promising anti-cancer activities. The xenograft animal model study with BPI-7711 & BPI-2021 (EGFR-TKI + cMet inhibitor) combination is currently in progress.

• Under IND Pre-clinical Study.
• Phase I Clinical Trial is expected in 2022.